Tpl2 Kinase Inhibitor 1

$80$1,760

Products Details

Product Description

– Tpl2 Kinase Inhibitor 1 is a 3-pyridylmethylamino analog, and is a selective Tpl2 inhibitor (IC50=50 nM). Tpl2 consists of COT kinase and MAP3K8. Tpl2 Kinase Inhibitor 1 plays an important role in the regulation of the inflammatory response and the progression of some cancers[1][2].

Web ID

– HY-12358

Storage Temperature

– -20°C, 3 years (Powder)

Shipping

– Blue Ice

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C21H14ClFN6

References

– [1]Gavrin LK, et al. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5288-92. |[2]Glatthar R, et al. Discovery of Imidazoquinolines as a Novel Class of Potent, Selective, and in Vivo Efficacious Cancer Osaka Thyroid (COT) Kinase Inhibitors. J Med Chem. 2016 Aug 25;59(16):7544-60.

CAS Number

– 871307-18-5

Molecular Weight

– 404.83

Compound Purity

– 99.22

SMILES

– N#CC1=C(NC2=CC=C(F)C(Cl)=C2)C3=CC(NCC4=CC=CN=C4)=NC=C3N=C1

Clinical Information

– No Development Reported

Research Area

– Cancer; Inflammation/Immunology

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– MAP3K;MAPKAPK2 (MK2);p38 MAPK

Isoform

– MAP3K8;p38 MAPK

Pathway

– MAPK/ERK Pathway

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=